Related Experiment Video

Updated: May 26, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Tumor-targeting drug delivery of new-generation taxoids

Iwao Ojima1, Edison S Zuniga, William T Berger

  • 1Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA. iojima@notes.cc.sunysb.edu

Future Medicinal Chemistry
|December 16, 2011
PubMed

Insights

Conventional chemotherapy lacks tumor specificity. Researchers developed novel drug conjugates using smart linkers and potent taxoids to target cancer cells, minimizing systemic toxicity for improved chemotherapy.

Area of Science:

  • Oncology
  • Drug Delivery
  • Molecular Chemistry

Background:

  • Conventional chemotherapy often lacks specificity, leading to systemic toxicity.
  • Tumor-targeting drug-delivery systems offer a strategy to enhance therapeutic efficacy.
  • Smart linkers are crucial for connecting cytotoxic agents to targeting molecules.

Purpose of the Study:

  • To review molecular approaches for designing novel drug-delivery systems.
  • To develop targeted chemotherapy using potent new-generation taxoids.
  • To improve tumor specificity and reduce systemic toxicity in cancer treatment.

Main Methods:

  • Designing drug conjugates with tumor-targeting molecules and 'smart' linkers.
  • Incorporating highly potent new-generation taxoids as cytotoxic agents.
  • Evaluating molecular strategies for targeted drug delivery in laboratory research.

Main Results:

  • Development of a novel drug-delivery system for targeted chemotherapy.
  • Demonstration of potential for specific delivery of cytotoxic drugs to tumors.
  • Indication of reduced systemic toxicity compared to conventional methods.

Conclusions:

  • Novel drug conjugates show promise for targeted cancer chemotherapy.
  • Molecular design of drug-delivery systems is key to enhancing specificity.
  • Further research in this area could lead to more effective cancer treatments.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...